GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » Shiller PE Ratio

TherapeuticsMD (TherapeuticsMD) Shiller PE Ratio : (As of Apr. 30, 2024)


View and export this data going back to 2007. Start your Free Trial

What is TherapeuticsMD Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


TherapeuticsMD Shiller PE Ratio Historical Data

The historical data trend for TherapeuticsMD's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Shiller PE Ratio Chart

TherapeuticsMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TherapeuticsMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TherapeuticsMD's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Shiller PE Ratio falls into.



TherapeuticsMD Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

TherapeuticsMD's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, TherapeuticsMD's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.06/129.4194*129.4194
=-0.060

Current CPI (Dec. 2023) = 129.4194.

TherapeuticsMD Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -3.000 99.695 -3.894
201406 -3.500 100.560 -4.504
201409 -6.000 100.428 -7.732
201412 -5.000 99.070 -6.532
201503 -6.500 99.621 -8.444
201506 -8.000 100.684 -10.283
201509 -5.500 100.392 -7.090
201512 -5.000 99.792 -6.484
201603 -5.500 100.470 -7.085
201606 -5.500 101.688 -7.000
201609 -6.500 101.861 -8.259
201612 -6.000 101.863 -7.623
201703 -5.500 102.862 -6.920
201706 -5.000 103.349 -6.261
201709 -3.500 104.136 -4.350
201712 -5.000 104.011 -6.221
201803 -5.500 105.290 -6.760
201806 -7.500 106.317 -9.130
201809 -8.000 106.507 -9.721
201812 -8.500 105.998 -10.378
201903 -8.000 107.251 -9.654
201906 -11.500 108.070 -13.772
201909 -6.500 108.329 -7.765
201912 -9.500 108.420 -11.340
202003 -10.500 108.902 -12.478
202006 -9.500 108.767 -11.304
202009 -6.000 109.815 -7.071
202012 -7.500 109.897 -8.832
202103 -5.671 111.754 -6.567
202106 -5.410 114.631 -6.108
202109 -5.620 115.734 -6.285
202112 -5.000 117.630 -5.501
202203 -5.700 121.301 -6.081
202206 12.830 125.017 13.282
202209 -3.130 125.227 -3.235
202212 8.100 125.222 8.372
202303 -0.370 127.348 -0.376
202306 -0.240 128.729 -0.241
202309 -0.320 129.860 -0.319
202312 -0.060 129.419 -0.060

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


TherapeuticsMD  (NAS:TXMD) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


TherapeuticsMD Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


TherapeuticsMD (TherapeuticsMD) Business Description

Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.
Executives
Marlan D Walker officer: General Counsel 951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Joseph Ziegler officer: Principal Financial Officer 1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan officer: CAO and VP of Finance 6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman officer: Chief Business Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts director C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Paul Bisaro director
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jules A. Musing director 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Collins Cooper C. director 33219 FOREST WEST DRIVE, MAGNOLIA TX 77354

TherapeuticsMD (TherapeuticsMD) Headlines

From GuruFocus

SHAREHOLDER ALERT: Weiss Law Investigates TherapeuticsMD, Inc.

By PRNewswire PRNewswire 06-20-2022